Clinical Trials Logo

Myasthenia Gravis, Juvenile Form clinical trials

View clinical trials related to Myasthenia Gravis, Juvenile Form.

Filter by:
  • None
  • Page 1

NCT ID: NCT05214612 Recruiting - Clinical trials for Nervous System Diseases

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Start date: January 1, 2022
Phase:
Study type: Observational

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

NCT ID: NCT03759366 Completed - Myasthenia Gravis Clinical Trials

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Start date: December 21, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity.